Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Second Patient In Phase 1 INO-3112 Trial, Sustains Full Remission After Treatment With PD-1 Checkpoint Inhibitor - FDA Headlines

Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Second Patient In Phase 1 INO-3112 Trial, Sustains Full Remission After Treatment With PD-1 Checkpoint Inhibitor  FDA Headlines

Jan 29, 2019 | Business. Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Second Patient In Phase 1. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has announced ...